Trade Names:Droperidol- Injection 2.5 mg/mL
Produces tranquilization, sedation and antiemetic effects, as well as mild alpha-adrenergic blockade, resulting in hypotension and decreased peripheral vascular resistance.
Vd is 1.5 L/kg (at steady-state). Biphasic distribution with a t ½ of approximately 1.4 min (rapid phase) and approximately 14.3 min (slower phase).
Approximately 75% excreted in the urine (1% as unchanged drug) and 22% excreted in feces. t ½ approximately 134 min.
3 to 10 min.
2 to 4 h.
Reduction of incidence of nausea and vomiting in surgical and diagnostic procedures.
Antiemetic in cancer chemotherapy.
Known or suspected QT prolongation (ie, QTc interval greater than 440 msec for men or greater than 450 msec for women), including patients with congenital long QT syndrome. Hypersensitivity to butyrophenones.
IM or slow IV 2.5 mg max recommended initial dose; additional 1.25 mg doses may be administered to achieve desired effect.Children (2 to 12 yr of age)
IM / IV 0.1 mg/kg max recommended initial dose, taking into account age and other clinical factors.
Compatible when mixed in syringe with atropine, butorphanol, chlorpromazine, fentanyl, glycopyrrolate, hydroxyzine, morphine, meperidine, perphenazine, promazine, promethazine, or scopolamine.
Store at room temperature and protect from light. Solution remains stable for 7 to 10 days.
Additive CNS depression may result.Diuretics, drugs known to increase the QT interval (eg, cisapride, pimozide)
Risk of life-threatening arrhythmias, including torsades de pointes, may be increased.
Barbiturates are physically incompatible with droperidol.
None well documented.
QT interval prolongation; torsades de pointes; cardiac arrest; ventricular tachycardia; hypotension.
Postoperative drowsiness; extrapyramidal effects (eg, dystonia, akathisia and oculogyric crisis); restlessness; hyperactivity; anxiety; dizziness; postoperative hallucinations; mental depression.
Respiratory depression; bronchospasm; laryngospasm.
Muscular rigidity; chills or shivering.
Contraindicated in patients with known or suspected QT prolongation.QT prolongation/torsades de pointes
Have been reported at or below recommended doses. Some cases have been in patients without known risk factors for QT prolongation. Some cases have been fatal. Perform baseline 12-lead ECG prior to initiation of therapy. Do not administer if QTc is greater than 440 msec in men or 450 msec in women. Use with extreme caution in patients at risk of developing prolonged QT syndrome (eg, CHF, bradycardia, diuretic use, cardiac hypertrophy, hypokalemia, hypomagnesemia, drugs that prolong QT interval, older than 65 yr of age, alcohol abuse, or taking benzodiazepines, volatile anesthetics, or IV opiates).Refractory disease
Reserve treatment in refractory disease because of serious proarrhythmic effects.
Monitor ECG prior to treatment and continue for 2 to 3 h after completing treatment to monitor for arrhythmias if the potential benefit outweighs the risk of potentially serious arrhythmias. Assess patient's respiratory status continuously. If patient is receiving narcotic analgesic concurrently, respiratory depression may occur. Note extrapyramidal symptoms.
Category C .
Safety and efficacy in children younger than 2 yr of age not established.
Decreased dose may be necessary. Use drug with caution in elderly, debilitated, and hepatically or renally impaired patients.
Rare cases of neuroleptic malignant syndrome (eg, altered consciousness, muscle rigidity, autonomic instability) have been reported.
Extension of pharmacologic effects, including QT prolongation, serious arrhythmias (eg, torsades de pointes), sedation, and hypotension.
Copyright © 2009 Wolters Kluwer Health.